News

ZEVALIN is used in the treatment of non-Hodgkin’s lymphoma (NHL) and MARQIBO is used in the treatment of acute lymphoblastic leukemia (ALL). CE melphalan has met the endpoints

Founded in 2003, HMT is a global leader in the emerging fields of metabolomics and systems biology. HMT will apply their proprietary, state-of-the-art capillary electrophoresis-mass spectrometry (CE-MS) technologies

The study will be conducted by way of a biOasis grant to the Brains for Brain Foundation ("B4B") of Padova, Italy, headed by renowned Lysosomal Storage Disease expert,

The all- natural, high performance products were developed together with Hard Core Beverages in Australia and Private Label Nutraceuticals in Georgia. The new formula is both gluten —

The FDA orphan drug status is based upon an estimated 40,000 procedures being performed in patients with these cancers. Navidea Interim CEO Michael Goldberg said this Orphan Drug

As part of the €465m deal, Boehringer will start clinical investigation of CV9202 in at least two different lung cancer settings, in combination with afatinib in patients with

The two firms will jointly discover and develop multiple ADCs, antibodies linked to cytotoxic drugs for more targeted delivery, using Sutro’s cell-free protein synthesis platforms Xpress CF and

The Phase III trial is designed to assess the efficacy and safety of plazomicin compared to colistin in patients with bloodstream infections and nosocomial pneumonia caused by carbapenem-resistant

All dosing in the drisapersen clinical program had been placed on hold by GSK on September 20, 2013, upon announcement of the DEMAND III study results. The re-dosing